HK1174330A1 - Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases ppar- - Google Patents

Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases ppar-

Info

Publication number
HK1174330A1
HK1174330A1 HK13101667.5A HK13101667A HK1174330A1 HK 1174330 A1 HK1174330 A1 HK 1174330A1 HK 13101667 A HK13101667 A HK 13101667A HK 1174330 A1 HK1174330 A1 HK 1174330A1
Authority
HK
Hong Kong
Prior art keywords
ppar
treatment
metabolic diseases
sparing
salts
Prior art date
Application number
HK13101667.5A
Other languages
English (en)
Chinese (zh)
Inventor
Gerard R Colca
Steven P Tanis
Scott D Larsen
Original Assignee
新陳代謝解決方案開發公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 新陳代謝解決方案開發公司 filed Critical 新陳代謝解決方案開發公司
Publication of HK1174330A1 publication Critical patent/HK1174330A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HK13101667.5A 2009-12-15 2013-02-06 Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases ppar- HK1174330A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28676509P 2009-12-15 2009-12-15
PCT/US2010/060439 WO2011084453A1 (en) 2009-12-15 2010-12-15 Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases

Publications (1)

Publication Number Publication Date
HK1174330A1 true HK1174330A1 (en) 2013-06-07

Family

ID=43501294

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13101667.5A HK1174330A1 (en) 2009-12-15 2013-02-06 Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases ppar-

Country Status (17)

Country Link
US (2) US8912335B2 (ja)
EP (1) EP2513070B1 (ja)
JP (1) JP5634526B2 (ja)
KR (3) KR102029611B1 (ja)
CN (1) CN102753539B (ja)
AU (1) AU2010340055B2 (ja)
CA (1) CA2783468C (ja)
DK (1) DK2513070T3 (ja)
ES (1) ES2658168T3 (ja)
HK (1) HK1174330A1 (ja)
HU (1) HUE038042T2 (ja)
MX (1) MX2012006725A (ja)
NO (1) NO2513070T3 (ja)
NZ (1) NZ600390A (ja)
PL (1) PL2513070T3 (ja)
RU (1) RU2564661C2 (ja)
WO (1) WO2011084453A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2783468C (en) 2009-12-15 2018-10-09 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
ES2688367T3 (es) 2012-12-21 2018-11-02 Sanofi Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
EP3024816B1 (en) 2013-07-22 2020-06-03 Metabolic Solutions Development Company LLC Ppar-sparing compounds for the treatment of metabolic diseases
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽-4(exendin-4)胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2019154958A1 (en) 2018-02-08 2019-08-15 Enyo Pharma Use of modulators of neet proteins for the treatment of infection
CN111689934B (zh) * 2020-06-24 2022-08-02 郑州大学 14-脱羟-13-脱氢穿心莲内酯-12-磺酸钾的单晶体及制备方法
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1985004170A1 (en) 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
WO1986002073A1 (en) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5143930A (en) 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
US5356913A (en) 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
SK109993A3 (en) * 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU706628B2 (en) 1995-07-03 1999-06-17 Sankyo Company Limited Treatment of arteriosclerosis and xanthoma
US7407978B2 (en) 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
JP2002543118A (ja) 1999-04-29 2002-12-17 シティ・オブ・ホープ ペントキシフィリン、ピオグリタゾンおよびメトフォルミンは、後期糖化最終生成物(age)の形成の阻害剤である
US6331596B1 (en) 1999-06-28 2001-12-18 Basf Corporation Method of preparing carbamate-functional polymers
SG148834A1 (en) 1999-06-30 2009-01-29 Japan Tobacco Inc Compounds for the modulation of ppary activity
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US20040087484A1 (en) 2000-12-01 2004-05-06 Sahota Pritam Singh Combination of organic compounds
HUP0400091A2 (hu) 2001-04-26 2004-06-28 Léciva, a.s. Eljárás antidiabetikus hatású pioglitazon előállítására
AU2002337749A1 (en) 2001-09-28 2003-04-07 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
AUPS236902A0 (en) 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EP1521753B1 (en) 2002-07-16 2007-09-05 Cadila Healthcare Ltd. A process to prepare pioglitazone via several intermediates.
US20060083784A1 (en) 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
US7230016B2 (en) 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
WO2005021542A2 (en) 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Process for the preparation of pioglitazone
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
JP4475983B2 (ja) 2004-03-03 2010-06-09 学校法人日本大学 Bmal1を阻害する方法
ES2393197T3 (es) 2004-09-28 2012-12-19 Otsuka Pharmaceutical Co., Ltd. Compuesto de carbostirilo
PL2001468T3 (pl) * 2006-03-16 2013-03-29 Metabolic Solutions Dev Co Llc Analogi tiazolidynodionu
EP2001470A2 (en) * 2006-03-16 2008-12-17 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues
AU2007227594B2 (en) 2006-03-16 2012-11-15 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
WO2009038681A1 (en) 2007-09-14 2009-03-26 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
BRPI0917567A2 (pt) * 2008-08-07 2015-11-17 Pulmagen Therapeutics Inflammation Ltd tratamento de doença respiratória
WO2010105048A1 (en) 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
WO2011017244A1 (en) 2009-08-05 2011-02-10 Metabolic Solutions Development Company Polymorphs of 5-(4-(2-(5-ethylpyridin-2-yl)-2-oxoethoxy)benzyl)-1,3-thiazolidine-2,4-dione (mitoglitazone)
KR20120092712A (ko) 2009-12-15 2012-08-21 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 진성 당뇨병 및 다른 대사성 질환의 치료를 위한 ppar 절약형 티아졸리딘디온 및 복합제
CA2783468C (en) 2009-12-15 2018-10-09 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
KR20120092714A (ko) 2009-12-15 2012-08-21 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 비만 및 다른 대사성 질환의 치료를 위한 ppar 절약형 티아졸리딘디온 및 복합제
MX2012006730A (es) 2009-12-15 2012-07-30 Metabolic Solutions Dev Co Llc Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas.
MX2012012095A (es) 2010-04-21 2012-12-17 Metabolic Solutions Dev Co Llc Analogos de tiazolidinadiona.

Also Published As

Publication number Publication date
KR20120107493A (ko) 2012-10-02
AU2010340055A1 (en) 2012-06-28
CN102753539A (zh) 2012-10-24
KR20180089569A (ko) 2018-08-08
KR20170044214A (ko) 2017-04-24
HUE038042T2 (hu) 2018-09-28
RU2012129930A (ru) 2014-01-27
KR102029560B1 (ko) 2019-10-07
AU2010340055B2 (en) 2014-07-24
DK2513070T3 (en) 2018-01-22
US20120309975A1 (en) 2012-12-06
NO2513070T3 (ja) 2018-04-07
CA2783468A1 (en) 2011-07-14
PL2513070T3 (pl) 2018-05-30
CN102753539B (zh) 2015-09-09
WO2011084453A1 (en) 2011-07-14
MX2012006725A (es) 2012-06-28
JP5634526B2 (ja) 2014-12-03
US9126959B2 (en) 2015-09-08
KR102029611B1 (ko) 2019-10-07
CA2783468C (en) 2018-10-09
JP2013514367A (ja) 2013-04-25
US20150051406A1 (en) 2015-02-19
EP2513070A1 (en) 2012-10-24
EP2513070B1 (en) 2017-11-08
US8912335B2 (en) 2014-12-16
NZ600390A (en) 2013-08-30
RU2564661C2 (ru) 2015-10-10
ES2658168T3 (es) 2018-03-08

Similar Documents

Publication Publication Date Title
HK1174330A1 (en) Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases ppar-
HK1258617A1 (zh) 雙重機制抑制劑用於治療疾病
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
PL2643004T3 (pl) Kompozycja oligosacharydów do leczenia chorób skóry
ZA201107449B (en) Compounds for the treatment of metabolic disorders
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
ZA201107446B (en) Compounds for the treatment of metabolic disorders
GB0904284D0 (en) Compounds for the treatment of metabolic disorders
GB0908193D0 (en) Treatment of disease state
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
PT2539352T (pt) Composições e métodos para tratar doenças cardíacas
EP2694465A4 (en) SUBSTITUTED ORTHOFLUOR COMPOUNDS FOR THE TREATMENT OF METABOLISM DISEASES
EP2544686A4 (en) COMBINED METHODS FOR THE TREATMENT OF DISEASES
EP2398789A4 (en) SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
GB201006167D0 (en) Compounds for the treatment of metabolic disorders
IL220134A0 (en) Thiazole derivatives for the treatment of diseases such as cancer
GB201006166D0 (en) Compounds for the treatment of metabolic disorders
EP2240024A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
GB0904286D0 (en) Compounds for the treatment of metabolic disorders
GB0904290D0 (en) Compounds for the treatment of metabolic disorders
GB0904288D0 (en) Compounds for the treatment of metabolic disorders
GB0904289D0 (en) Compounds for the treatment of metabolic disorders
GB201004744D0 (en) Compounds for the treatment of metabolic disorders